HYD1 peptides as anti-cancer agents
View Patent ↗The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as myeloma. The present invention further includes a method of increasing the efficacy of chemotherapy and radiation therapy, comprising administering an agent that binds β1 integrin to a patient in need thereof. In one embodiment, the β1 integrin binding agent is the HYD1 peptide, or a functional fragment or variant thereof. In another aspect, the invention pertains to a composition (an adhesion trap) comprising a substrate (also referred to as a surface or support) with a HYD1 peptide, or fragment or variant thereof, immobilized to the substrate, and a method of removing circulating tumor cells (CTC) from blood by contacting a subject's blood with the immobilized peptide. Another aspect of the invention concerns a method of identifying modulators of peptide binding. Another aspect of the invention concerns a method for detecting CTC.
1. A method of treating a proliferation disorder in a subject, comprising administering an effective amount of at least one isolated peptide, or a polynucleotide encoding the at least one peptide, to the subject, wherein the at least one peptide is KIKMVISWKG (HYD1; SEQ ID NO:1) AIAMVISWAG (SEQ ID NO:2; HYD8); AIKMVISWAG (SEQ ID NO:3; HYD6); AIKMVISWKG (SEQ ID NO:4; HYD2); AKMVISW (SEQ ID NO:5); AKMVISWKG (SEQ ID NO:6); IAMVISW (SEQ ID NO:7); IAMVISWKG (SEQ ID NO:8); IKAVISW (SEQ ID NO:9); IKAVISWKG (SEQ ID NO:10); IKMAISW (SEQ ID NO:11); IKMAISWKG (SEQ ID NO:12); IKMVASW (SEQ ID NO:13); IKMVASWKG (SEQ ID NO:14); IKMVIAW (SEQ ID NO:15); IKMVIAWKG (SEQ ID NO:16); IKMVISA (SEQ ED NO:17); IKMVISAKG (SEQ ID NO:18); IKMVISW (SEQ ID NO:19); IKMVISWAG (SEQ ID NO:20); KMVISWKA (SEQ ID NO:21); IKMVISWKG (SEQ ID NO:22; HYD18; (−K)HYD1); ISWKG (SEQ ID NO:23); KAKMVISWKG (SEQ ID NO:24); KIAMVISWAG (SEQ ID NO:25; HYD7); KIAMVISWKG (SEQ ID NO:26); KIKAVISWKG (SEQ ID NO:27); KIKMAISWKG (SEQ ID NO:28); KIKMV (SEQ ID NO:29); KIKMVASWKG (SEQ ID NO:30); KIKMVI (SEQ ID NO:31; HYD16); KIKMVIAWKG (SEQ ID NO:32); KIKMVIS (SEQ ID NO:33; HYD15): KIKMVISAKG (SEQ ID NO:34); KIKMVISW (SEQ ID NO:35; HYD14); KIKMVISWAG (SEQ ID NO:36); KIKMVISWK (SEQ ID NO:37; HYD17; HYD1(−G)); KIKMVISWKA (SEQ ID NO:38); KMVISWKG (SEQ ID NO:39; HYD9); LSWKG (SEQ ID NO:40; HYD12); MVISWKG (SEQ ID NO:41; HYD10); SWKG (SEQ ID NO:42: HYD13); VISWKG (SEQ ID NO:43; HYD11); WIKSMKIVKG (SEQ ID NO:44); KMVIXW (SEQ ID NO:46); IKMVISWXX (SEQ ID NO:48); or KMVISWXX (SEQ ID NO:49); wherein X is any amino acid.
2. The method of claim 1 , wherein the at least one peptide is modified by the addition of biotin, cystein, or carboxyfluorescein (FAM) to the C-terminus or N-terminus of the peptide.
3. The method of claim 1 , wherein the at least one peptide comprises at least one D-ammo acid.
4. The method of claim 1 , wherein the proliferation disorder is cancer.
5. The method of claim 1 , wherein the at least one peptide is administered locally at the site of the proliferation disorder.
6. The method of claim 1 , wherein the proliferation disorder is cancer, and wherein the at least one peptide induces cell death in circulating tumor cells.
7. The method of claim 1 , wherein the proliferation disorder is cancer, and wherein the at least one peptide prevents or delays onset of metastasis to bone.
8. The method of claim 1 , wherein the subject is not suffering from the proliferation disorder, and wherein the at least one peptide is administered to delay onset of the proliferation disorder.
9. The method of claim 1 , wherein the subject is human.
10. The method of claim 1 , wherein the proliferation disorder is a drug resistant cancer.
11. The method of claim 1 , further comprising administering at least one anti-cancer agent to the subject before, during, or after said administering of the at least one peptide.
12. The method of claim 1 , wherein the proliferation disorder is a cancer characterized by β1 integrin signaling or β1 integrin mediated adhesion.
13. The method of claim 1 , wherein the proliferation disorder is characterized by a proliferation of T cells.
14. The method of claim 1 , wherein the subject is also treated with chemotherapy or radiation therapy.
15. The method of claim 1 , wherein the at least one peptide is provided in a composition comprising at least one pharmaceutically acceptable carrier.
16. The method of claim 1 , wherein the at least one peptide is provided as a pharmaceutically acceptable salt.